Vimentin Mouse Monoclonal Antibody [A6-C1] (M1412-1)
Catalog# M1412-1
Mouse Monoclonal to Vimentin
-
WB
-
IF-Cell
-
IHC-P
-
Human
-
Mouse
-
Rat
Western blot analysis of Vimentin on different lysates with Mouse anti-Vimentin antibody (M1412-1) at 1/2,000 dilution.
Lane 1: HeLa cell lysate
Lane 2: C2C12 cell lysate
Lane 3: L6 cell lysate
Lane 4: Daudi cell lysate (negative)
Lysates/proteins at 20 µg/Lane.
Predicted band size: 54 kDa
Observed band size: 54 kDa
Exposure time: 24 seconds;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (M1412-1) at 1/2,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1/50,000 dilution was used for 1 hour at room temperature.
Specifications
Product Type
Mouse monoclonal primary
Product Name
Vimentin Mouse Monoclonal Antibody [A6-C1] (M1412-1)
Immunogen
Synthetic peptide within human vimentin aa 1-50 / 466.
Host
Mouse
Positive Control
HeLa cell lysate, C2C12 cell lysate, L6 cell lysate, HeLa, human kidney tissue.
Conjugation
Unconjugated
Clonality
Monoclonal
Clone Number
A6-C1
RRID
APPLICATION DILUTION
-
WB
-
1:2,000
-
IF-Cell
-
1:100-1:200
-
IHC-P
-
1:400
PROPERTIES
Form
Liquid
Storage Condition
Shipped at 4℃. Store at +4℃ short term (1-2 weeks). It is recommended to aliquot into single-use upon delivery. Store at -20℃ long term.
Storage Buffer
1*PBS (pH7.4), 0.2% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Concentration
2ug/ul
Purification
Protein A affinity purified.
Molecular Weight
Predicted band size: 54 kDa
Isotype
IgG2b
TARGET
UNIPROT #
PROTEIN NAME
Vimentin
SYNONYMS
CTRCT30 antibody;Epididymis luminal protein 113 antibody;FLJ36605 antibody;HEL113 antibody;VIM antibody;VIME_HUMAN antibody;Vimentin antibody
SEQUENCE SIMILARITIES
Belongs to the intermediate filament family.
TISSUE SPECIFICITY
Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.
POST-TRANSLATIONAL MODIFICATION
Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin (By similarity). One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm. Phosphorylated by STK33. Phosphorylated on tyrosine residues by SRMS.; O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status.; S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.
SUBCELLULAR LOCATION
Cytoplasm, cytoskeleton, Nucleus matrix, Cell membrane.
FUNCTION
Vimentin is a type III intermediate filament (IF) protein that is expressed in mesenchymal cells. Vimentin plays a significant role in supporting and anchoring the position of the organelles in the cytosol. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. In essence, vimentin is responsible for maintaining cell shape, integrity of the cytoplasm, and stabilizing cytoskeletal interactions. Vimentin has been shown to eliminate toxic proteins in JUNQ and IPOD inclusion bodies in asymmetric division of asymmetric division of mammalian cell lines. It has been used as a sarcoma tumor marker to identify mesenchyme. Methylation of the vimentin gene has been established as a biomarker of colon cancer and this is being utilized in the development of fecal tests for colon cancer. High levels of DNA methylation in the promotor region have also been associated with markedly decreased survival in hormone positive breast cancers.
CITATIONS
-
Yuan, J., Jiang, X., Lan, H., Zhang, X., Ding, T., Yang, F., Zeng, D., Yong, J., Niu, B., & Xiao, S.
Multi-Omics Analysis of the Therapeutic Value of MAL2 Based on Data Mining in Human Cancers
-
WB
-
Human
-
Citation
-
-
Zhao Xiaobao,et al
Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2 H,4 H)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer
-
WB
-
Human
-
Citation
-
-
Li, X., Jiang, S., Jiang, T., Sun, X., Guan, Y., Fan, S., & Cheng, Y.
LEM Domain Containing 1 Acts as a Novel Oncogene and Therapeutic Target for Triple-Negative Breast Cancer
-
WB
-
Human
-
Citation
-
-
Feng, Z. H., Zheng, L., Yao, T., Tao, S. Y., Wei, X. A., Zheng, Z. Y., Zheng, B. J., Zhang, X. Y., Huang, B., Liu, J. H., Chen, Y. L., Shan, Z., Yuan, P. T., Wang, C. G., Chen, J., Shen, S. Y., & Zhao, F. D.
EIF4A3-induced circular RNA PRKAR1B promotes osteosarcoma progression by miR-361-3p-mediated induction of FZD4 expression
-
WB
-
IHC
-
Citation
-
-
Luo, S., Wang, W., Feng, J., & Li, R.
TEX10 Promotes the Tumorigenesis and Radiotherapy Resistance of Urinary Bladder Carcinoma by Stabilizing XRCC6
-
WB
-
Citation
-
-
Gang Feng
Tex10 promotes stemness and EMT phenotypes in esophageal squamous cell carcinoma via the Wnt/β-catenin pathway
-
WB
-
Human
-
Citation
-
